Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma by Avivi, Irit, Balaban, Roi, Shragai, Tamir, Sheffer, Gabi, Morales, Miguel, Aharon, Anat, Lowenton‐Spier, Noa, Trestman, Svetlana, Perry, Chava, Benyamini, Noam, Mittelman, Moshe, Tabib, Yaara, Bar Lev, Tali, Zavaro, Mor, Herishanu, Yair, Luttwak, Efrat, Cohen, Yael C.

Request full text

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class E... by Cohen, Yael C., Shragai, Tamir, Lavi, Noa, Vaxman, Iuliana, Chubar, Evgeni, Gatt, Moshe E, Ganzel, Chezi, Magen, Hila, Luttwak, Efrat, Mittelman, Moshe, Tzoran, Inna, Vainstein, Vladimir, Lowenton-Spier, Noa, Melamed, Natan, Krayzler, Ella, Pereg, Ilana, Avivi Mazza, Irit

Get full text

Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test by Avivi, Irit Mazza, Neaman, Miriam, Lowenton-Spier, Noa, Perry, Chava, Joffe, Erel, Vitkon, Roy, Bogol, Vlada, Michaeli, Yael, Gilat, Noa, Itelson, Lynne, Zirkin, Shahar, Deek, Jasline, Kastritis, Efstathios, Sablauskas, Karolis, Cernauskiene, Skirmante, Vaitekėnaitė, Vilmantė, Zucenka, Andrius, Papajik, Tomas, Kriegova, Eva, Gajdos, Petr, Ebenstein, Yuval

Get full text

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Pro... by Shmuel, Ronit, Tellem, Rotem, Gatt, Moshe E, Lavi, Noa, Ganzel, Chezi, Luttwak, Efrat, Chubar, Evgeni, Rouvio, Ory, Vaxman, Iuliana, Pasvolsky, Oren, Ballan, Mouna, Tadmor, Tamar, Nemets, Anatoly, Jarchowcky, Osnat, Shvetz, Olga, Lieba, Merav, Shpilberg, Ofer, Lowenton-Spier, Noa, Dally, Najib, Avivi Mazza, Irit, Cohen, Yael C.

Get full text

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Tripl... by Cohen, Yael C, Shragai, Tamir, Lavi, Noa, Vaxman, Iuliana, Chubar, Evgeni, Gatt, Moshe E, Ganzel, Chezi, Magen, Hila, Luttwak, Efrat, Lowenton-Spier, Noa, Gez-Aaronson, Liron, Melamed, Natan, Avivi, Irit

Get full text

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Tran... by Cohen, Yael C, Gatt, Moshe E, Luttwak, Efrat, Lavi, Noa, Ganzel, Chezi, Chubar, Evgeni, Rouvio, Ory, Vaxman, Iuliana, Pasvolsky, Oren, Ballan, Mouna, Tadmor, Tamar, Nemets, Anatoly, Jarchowsky, Osnat, Shvetz, Olga, Shpilberg, Ofer, Dally, Najib, Leiba, Merav, Weiner, Assaf, Zada, Mor, Wang, Shuang-Yin, Gur, Chamutal, Lowenton-Spier, Noa, Goor-Porges, Liron, Amit, Ido, Avivi, Irit

Get full text

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) by Cloughesy, Timothy F, Brenner, Andrew, de Groot, John F, Butowski, Nicholas A, Zach, Leor, Campian, Jian L, Ellingson, Benjamin M, Freedman, Laurence S, Cohen, Yael C, Lowenton-Spier, Noa, Rachmilewitz Minei, Tamar, Fain Shmueli, Shifra, Wen, Patrick Y

Get full text

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study by Brenner, Andrew J, Peters, Katherine B, Vredenburgh, James, Bokstein, Felix, Blumenthal, Deborah T, Yust-Katz, Shlomit, Peretz, Idit, Oberman, Bernice, Freedman, Laurence S, Ellingson, Benjamin M, Cloughesy, Timothy F, Sher, Naamit, Cohen, Yael C, Lowenton-Spier, Noa, Rachmilewitz Minei, Tamar, Yakov, Niva, Mendel, Itzhak, Breitbart, Eyal, Wen, Patrick Y

Get full text

ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY I... by Cloughesy, Timothy, Brenner, Andrew J, Butowski, Nicholas, Cohen, Yael C, Lowenton-Spier, Noa, Wen, Patrick

Get full text

NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111... by Ellingson, Benjamin, Cloughesy, Timothy, Wang, Chencai, Patel, Kunal, Raymond, Catalina, Brenner, Andrew, de Groot, John, Butowski, Nicholas, Zach, Leor, Campian, Jian, Schlossman, Jacob, Rizvi, Shan, Cohen, Yael, Lowenton-Spier, Noa, Minei, Tamar Rachmilewitz, Fain-Shmueli, Shifra, Wen, Patrick

Get full text

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma by Ellingson, Benjamin M, Patel, Kunal, Wang, Chencai, Raymond, Catalina, Brenner, Andrew, de Groot, John F, Butowski, Nicholas A, Zach, Leor, Campian, Jian L, Schlossman, Jacob, Rizvi, Shan, Cohen, Yael C, Lowenton-Spier, Noa, Minei, Tamar Rachmilewitz, Shmueli, Shifra Fain, Wen, Patrick Y, Cloughesy, Timothy F

Get full text